Hypofractionated Radiation Therapy with Adaptive Planning for the Treatment of Endometrial and Cervical Cancer, HERA Trial

This phase I clinical trial studies the side effects of hypofractionated radiation therapy with adaptive planning, and to see how well it works in treating women with endometrial or cervical cancer. Many women receive radiation to the pelvis after they have undergone surgery to remove the main endometrial and/or cervical tumor. Standard radiation therapy to the pelvis is given daily (Monday-Friday) for 5-6 weeks. This can be a significant obstacle and burden for patients. Adaptive planning uses images from computed tomography (CT) or magnetic resonance imaging (MRI) to help guide the radiation beam during radiation therapy. This helps to make radiation therapy more accurate and cause less damage to healthy tissue. This can allow for radiation treatments to be delivered as fewer but larger doses, which is called hypofractionation. Giving hypofractionated radiation therapy with adaptive planning may be safe, tolerable, and/or effective in treating women with endometrial or cervical cancer.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06538337.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center

Principal InvestigatorPuja Venkat

• Primary ID23-001976
• Secondary IDsNCI-2024-06196
• ClinicalTrials.gov IDNCT06538337